Regeneron (REGN) announced an expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of Regeneron’s ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to ...

$3 billion FUJIFILM deal will nearly double Regeneron’s large-scale U.S. biologics manufacturing capacity over the next decade. Regeneron adds 7,000+ U.S. jobs in five years, with $7B+ in ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron ... the U.S. Attorney's Office for the District ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms ...

Regeneron Pharmaceuticals has announced a new ... or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual ...

Under a new 10-year agreement, Regeneron will pay CDMO powerhouse Fujifilm Diosynth Biotechnologies more than $3 billion to help manufacture bulk drug product for its commercial biologics in the ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of ... and the U.S. Attorney's Office for the District of ...

Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies to double its large-scale manufacturing in the U.S. Regeneron's new investment with ...

A deal between Regeneron and Fujifilm Diosynth Biotechnologies will fund a $3B expansion at the latter’s facility in Holly Springs, North Carolina. The 10-year agreement will allow Regeneron ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion ...